"Natural History" Clinical Trials: An Enduring Contribution to Modern Medical Practice, E.M. Scolnick, E.E. Slater, and G.W. Williams:
Role of the Pharmaceutical Industry in Clinical Trials.
Use of "Natural History" RCTs to Validate the Cholesterol Hypothesis and Support Changes in the Management of Other Conditions.
Development of a New Chemical Entity.
"Natural History" RCTs: Some Considerations.
Clinical Trials and the Practice of Medicine in the Age of Genomics.
Angiotensin-Converting Enzyme Inhibitors, J. Menard and A. Patchett:
Clinically Available ACE Inhibitors.
Contribution of ACE Inhibitors to the Growth of Physiological and Pathophysiological Knowledge.
Biological Advances in the Knowledge of ACE That Evolved in Parallel with the Drug Development Process.
Clinical Development Process of ACE Inhibitors in Hypertension.
Benefits of ACE Inhibition Beyond the Fall in Blood Pressure.
ACE Inhibitors and Congestive Heart Failure.
ACE Inhibitors and Myocardial Infarction.
ACE Inhibitors, Coronary Heart Disease, and Atherosis.
ACE Inhibitors and Prevention of Restenosis.
ACE Inhibitors and Renal Insufficiency.
The Fallacy of the Concepts of Normotension and Hypertension and the Cardiovascular Protective Effects of ACE Inhibitors.
Surrogate End Points in Clinical Trials of ACE Inhibition: Are We Being Misled?
HMG-CoA Reductase Inhibitors, R. Illingworth and J.A. Tolbert: